• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Health advocate coalition says EMA advice for fee undermines independence of regulatory authorities

Health advocate coalition says EMA advice for fee undermines independence of regulatory authorities

September 15, 2014
CenterWatch Staff

Health Action International Europe (HAI Europe), the International Society of Drug Bulletins (ISDB), the Medicines in Europe Forum (MiEF) and the Association Internationale de la Mutualité (AIM) have criticized the EMA for providing confidential “advice” to pharmaceutical companies on their development plans for new medicines in exchange for fees—a potentially harmful practice the EMA now is trying to extend to national health technology assessment (HTA) bodies in the E.U.

The coalition of medicines advocates made the criticism in a joint response to the EMA’s public consultation on its Best practice guidance for pilot EMA HTA parallel scientific advice procedures, which closed July 14.

“There is immense potential for conflicts of interest to arise when the EMA, through its Committee for Medicinal Products for Human Use, provides advice about specific pharmaceutical products in exchange for fees, then later decides the marketing authorization for these products,” said Ancel.la Santos Quintano, policy advisor with HAI Europe. “This dubious practice should be ended, not refined and broadened to HTA bodies.”

HTA bodies are widely consulted throughout the E.U. They determine the “therapeutic added value” and appropriate level of financial reimbursement for new medicines. If a new medicine provides no additional therapeutic value in comparison with safer and cheaper well-established treatments, yet receives authorization from drug regulatory agencies, HTA bodies can recommend that it does not receive reimbursement. This limits European patients’ exposure to potential avoidable adverse drug reactions and helps minimize member states’ healthcare expenditures.

“When the EMA and national HTA bodies sell scientific advice to pharmaceutical companies to aid in drug development, they essentially become co-developers of medicines and financially dependent on the pharmaceutical industry,” said Joerg Schaaber, president of the ISDB. “Establishing financial and business ties with the pharmaceutical industry undermines the independence of HTA bodies, as well as the critical roles that both the EMA and HTA bodies have in protecting public health.”

HAI Europe, ISDB, MiEF and AIM also are concerned that the EMA describes the scientific advisory process between it, HTA bodies and the pharmaceutical industry as “confidential” in its draft guidance document.

“Public institutions, such as the EMA, must at all times be transparent and accountable,” said Pierre Chirac, coordinator with the MiEF. “Advice to pharmaceutical companies by drug regulatory authorities and HTA bodies is not only unnecessary if scientific data is robust and clinical trials are designed to address legitimate public health needs, but dangerous because of its potential to result in regulatory capture, particularly when the process is conducted in secrecy.”

Instead of providing customized advice to pharmaceutical companies, the coalition of medicines advocates recommend the EMA continues developing guidelines that help drug manufacturers make development decisions that address genuine public health needs. It also urges HTA bodies, in their development of in-depth reviews, to refuse early discussions about drug development with the EMA and pharmaceutical companies and instead require full access to clinical trial data and complete assessment reports for medicines.

The EMA has provided scientific advice for a fee to the pharmaceutical industry since 2005. The same practice was applied to HTA bodies in 2010 under a pilot project. In March 2014, the EMA also launched an “adaptive licensing” project, which “builds on existing regulatory processes and intends to extend the use of elements that are already in place, including scientific advice.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing